• Ping An Biomedical swung to net income of RMB 4.83 million for the six months ended March 31, 2026, from a net loss a year earlier.
• Revenue fell 47.38% to RMB 9.59 million, while operating income turned positive at RMB 537,604.
• Basic and diluted earnings per share swung to RMB 0.10 from a loss a year earlier.
• Other income rose to RMB 5.75 million, including a RMB 5.67 million fair-value gain on equity investments.
• Cash and bank balances increased to RMB 6.84 million as of March 31, 2026, while total assets climbed to RMB 100.22 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ping An Biomedical Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098994), on September 11, 2026, and is solely responsible for the information contained therein.